MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR

The present invention features a compound of formula I:or a pharmaceutically acceptable salt thereof, where R1, R2, R3, W, X, Y, Z, n, o, p, and q are defined herein, for the treatment of CFTR mediated diseases, such as cystic fibrosis. The present invention also features pharmaceutical compositions...

Full description

Saved in:
Bibliographic Details
Main Authors KHATUYA, Haripada, JOSHI, Pramod Virupax, HADIDA-RUAH, Sara Sabina, MCCARTNEY, Jason, CLEVELAND, Thomas, GROSS, Raymond Stanley, SILINA, Alina, MARELIUS, Gulin Erdogan, PIERRE, Fabrice Jean Denis, KRENITSKY, Paul John, GROOTENHUIS, Peter Diederik Jan, COON, Timothy Richard, CLEMENS, Jeremy J, ZHOU, Jinglan, ANDERSON, Corey, MILLER, Mark Thomas, LIN, Chun-Chieh, ARUMUGAM, Vijayalaksmi, BINCH, Hayley Marie, FRIEMAN, Bryan A, NICHOLLS, Georgia McGaughey, TERMIN, Andreas P, BEAR, Brian Richard, UY, Johnny, MELILLO, Vito, CONROY, Erica
Format Patent
LanguageEnglish
French
German
Published 05.04.2023
Subjects
CHEMISTRY
HETEROCYCLIC COMPOUNDS
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online AccessGet full text

Cover

More Information
Summary:The present invention features a compound of formula I:or a pharmaceutically acceptable salt thereof, where R1, R2, R3, W, X, Y, Z, n, o, p, and q are defined herein, for the treatment of CFTR mediated diseases, such as cystic fibrosis. The present invention also features pharmaceutical compositions, method of treating, and kits thereof.
Bibliography:Application Number: EP20220194095